NAD+

Quick Facts

Introduction

NAD+ (nicotinamide adenine dinucleotide) is not a peptide but a dinucleotide coenzyme found in every living cell, and it is included in this research library because it has become a central molecule in longevity and metabolic research. It is studied both as the classic carrier of electrons in cellular respiration and, more recently, as a limiting substrate for a family of enzymes — sirtuins, PARPs, and CD38 — that govern aging-related signaling. In that role it is frequently discussed alongside other longevity-oriented compounds such as Epitalon and mitochondrial peptides like SS-31 and MOTS-C.

The conceptual appeal of NAD+ research is the observation that cellular NAD+ levels decline with age across many tissues. Because so many repair and energy pathways depend on NAD+ as a substrate, researchers study whether this decline is a contributor to age-associated dysfunction and whether restoring NAD+ — directly or via precursors — affects those pathways in preclinical models.

This profile covers what NAD+ is, its molecular characteristics, its dual redox and signaling mechanisms, the mitochondrial and longevity research it appears in, and how it compares with NAD+ precursors and related mitochondrial peptides. Related entries are catalogued in the peptide database.

What is NAD+?

NAD+ is a dinucleotide built from two nucleotides — one bearing an adenine base, the other a nicotinamide base — joined through a pair of phosphate groups. The nicotinamide ring is the chemically active part: it accepts and donates a hydride ion, cycling between the oxidized form NAD+ and the reduced form NADH. This reversible redox couple is one of the most fundamental in all of biochemistry.

Cells maintain NAD+ through several routes: de novo synthesis from tryptophan, and salvage pathways that recycle nicotinamide and use precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Much applied research focuses on these precursors precisely because supplying NAD+ itself is constrained by its size, charge, and limited stability — characteristics that distinguish it sharply from the peptides in this library.

Molecular and structural characteristics

Structurally, NAD+ comprises an adenine dinucleotide linked to a nicotinamide mononucleotide via a phosphoanhydride bridge. The molecule carries multiple negative charges at physiological pH due to its phosphate groups, which is part of why it does not freely cross cell membranes — a key practical contrast with the small, sometimes membrane-permeant peptides studied for longevity.

The reactive site is the C4 position of the nicotinamide ring, where hydride transfer occurs. Whether NAD+ acts as a redox cofactor or as an enzymatic substrate, this nicotinamide moiety is the business end of the molecule; sirtuins and PARPs, for example, cleave the bond between nicotinamide and ribose to drive their reactions.

Mechanism of action

NAD+ operates through two broad mechanisms. The first is its classic redox role: as NAD+/NADH it shuttles electrons through glycolysis, the citric-acid cycle, and oxidative phosphorylation, making it indispensable for ATP production. In this capacity NAD+ is continually recycled and is not consumed, simply oscillating between oxidized and reduced states.

The second mechanism — the focus of most longevity research — is its role as a consumable substrate for several enzyme families. Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, and stress resistance; their activity is directly tied to NAD+ availability. PARP enzymes consume NAD+ during DNA-damage repair, and CD38 is a major NAD+-consuming enzyme whose activity rises with age and inflammation.

Because sirtuins, PARPs, and CD38 all draw on the same NAD+ pool, researchers study NAD+ as a shared currency linking energy metabolism, genomic maintenance, and inflammatory signaling. This integrative role is why NAD+ is examined in the same research conversations as mitochondrial peptides such as SS-31 and MOTS-C, and broader longevity compounds like Humanin.

• Redox cofactor (NAD+/NADH) driving ATP-generating metabolism.
• Required substrate for sirtuin (SIRT1–7) deacylase activity.
• Consumed by PARP enzymes during DNA-damage repair.
• Substrate for CD38 and related NAD+-consuming signaling enzymes.

Mitochondrial bioenergetics research

Mitochondria are where NAD+ exerts its most concentrated metabolic influence. The NAD+/NADH ratio is a primary determinant of flux through the electron transport chain, and shifts in this ratio are studied as readouts of metabolic state. Preclinical research has associated declining mitochondrial NAD+ with reduced respiratory capacity and impaired stress resistance in aged tissues.

Restoring NAD+ — most often via precursors such as NMN and NR in animal models — has been associated with improved mitochondrial function, enhanced sirtuin signaling (notably mitochondrial SIRT3), and changes in markers of metabolic health. These observations place NAD+ biology adjacent to peptide research on mitochondrial integrity, including SS-31, which targets the inner mitochondrial membrane, and MOTS-C, a mitochondrial-derived peptide studied for metabolic signaling.

Longevity and DNA-repair research

NAD+ sits at the heart of several hallmarks of aging. Through sirtuins it is linked to epigenetic regulation and genomic stability; through PARPs it is tied to the DNA-damage response. A widely discussed model proposes that accumulating DNA damage with age increases PARP activity, which drains NAD+ and in turn starves sirtuins — connecting genomic maintenance and metabolic decline through a single limiting molecule.

The age-related rise in CD38 is another active research thread, studied as a major driver of NAD+ depletion in aging and inflammation. Together these pathways frame NAD+ as a potential node in longevity biology, and they explain why it is grouped with compounds such as Epitalon and Humanin in longevity-research discussions, even though its chemistry and mechanism are entirely distinct from those peptides.

Comparison: NAD+ vs NAD+ precursors vs mitochondrial peptides

NAD+ is most often compared with its precursors (NMN and NR), which are used to raise NAD+ indirectly, and contrasted with mitochondrial peptides such as SS-31 that support energy metabolism through different mechanisms. All appear in mitochondrial and longevity research but act in distinct ways.

Researchers studying mitochondrial energetics frequently examine NAD+ alongside SS-31 and MOTS-C. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

NAD+ pharmacokinetics are dominated by its poor membrane permeability and rapid turnover. Intracellular NAD+ is continuously synthesized and consumed, with pool turnover measured in hours in metabolically active tissues. Because the charged molecule does not readily enter cells, much research effort focuses on precursors that are transported more efficiently and then converted to NAD+ inside the cell.

When NAD+ itself is administered in research settings, a substantial fraction is thought to be broken down extracellularly into nicotinamide and other metabolites before reaching tissues, where it re-enters salvage pathways. This degradative behavior is the key interpretive variable in NAD+ studies and the main reason precursor strategies are so prominent in the literature.

Reconstitution and handling considerations

Lyophilized NAD+ is reconstituted with sterile or bacteriostatic water. Unlike many peptides, NAD+ in solution is comparatively labile — sensitive to heat, repeated freeze–thaw, and pH extremes — so solutions are best prepared fresh, kept cold, and used promptly. The diluent should be added gently and the vial swirled rather than shaken; the solution should be clear, and any cloudiness or discoloration indicates it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent gently; swirl rather than shaking.
• Prepare solutions fresh and keep them cold; NAD+ degrades faster than peptides.
• Confirm the solution is clear and uncolored before use.
• Protect from light, heat, and repeated freeze–thaw cycles.

Storage considerations

Lyophilized NAD+ is most stable frozen at −20 °C (or colder), kept dry and shielded from light. Reconstituted solution is refrigerated at 2–8 °C and used within a short window because of its limited aqueous stability. Aliquoting before freezing minimizes freeze–thaw exposure, which is especially important for this molecule.

Research limitations

NAD+ biology is well established, but its application as a longevity intervention is far less settled. Most encouraging longevity data come from cell and animal models, frequently using precursors rather than NAD+ itself. Human trials of precursors reliably raise NAD+ markers in blood, yet translation to durable clinical outcomes remains under investigation, and the bioavailability of administered NAD+ is constrained by its chemistry. It is described here strictly for research reference.

• Much longevity evidence is preclinical and uses precursors (NMN/NR).
• NAD+ itself is poorly membrane-permeant and unstable in solution.
• Raising NAD+ markers does not by itself prove clinical benefit.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015.Source
2. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018.Source
3. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021.Source